
KTTA Stock Forecast & Price Target
KTTA Analyst Ratings
Bulls say
Pasithea Therapeutics is poised to make a significant impact in the treatment of NF1 and other diseases, and their strong pipeline and potential for growth make them a promising investment opportunity.
Bears say
Pasithea Therapeutics is a biotechnology company focused on developing treatments for central nervous system disorders and other diseases. While their current pipelines show potential promise, the company faces several challenges, including regulatory hurdles, a limited market for their treatments, and competition from traditional MEK inhibitors. Additionally, their valuation is based on assumptions and may be subject to change as their clinical trials progress. Ultimately, the success of Pasithea Therapeutics will depend on their ability to effectively navigate these challenges and bring their treatments to market.
This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.
KTTA Analyst Forecast & Price Prediction
Start investing in KTTA
Order type
Buy in
Order amount
Est. shares
0 shares